Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST).
Gheorghiade M, Orlandi C, Burnett JC, Demets D, Grinfeld L, Maggioni A, Swedberg K, Udelson JE, Zannad F, Zimmer C, Konstam MA. Gheorghiade M, et al. Among authors: zannad f. J Card Fail. 2005 May;11(4):260-9. doi: 10.1016/j.cardfail.2005.03.009. J Card Fail. 2005. PMID: 15880334 Clinical Trial.
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Konstam MA, et al. Among authors: zannad f. JAMA. 2007 Mar 28;297(12):1319-31. doi: 10.1001/jama.297.12.1319. Epub 2007 Mar 25. JAMA. 2007. PMID: 17384437 Clinical Trial.
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Gheorghiade M, et al. Among authors: zannad f. JAMA. 2007 Mar 28;297(12):1332-43. doi: 10.1001/jama.297.12.1332. Epub 2007 Mar 25. JAMA. 2007. PMID: 17384438 Clinical Trial.
Epidemiology of acute heart failure syndromes.
Alla F, Zannad F, Filippatos G. Alla F, et al. Among authors: zannad f. Heart Fail Rev. 2007 Jun;12(2):91-5. doi: 10.1007/s10741-007-9009-2. Heart Fail Rev. 2007. PMID: 17450426 Review.
Overview of emerging pharmacologic agents for acute heart failure syndromes.
De Luca L, Mebazaa A, Filippatos G, Parissis JT, Böhm M, Voors AA, Nieminen M, Zannad F, Rhodes A, El-Banayosy A, Dickstein K, Gheorghiade M. De Luca L, et al. Among authors: zannad f. Eur J Heart Fail. 2008 Feb;10(2):201-13. doi: 10.1016/j.ejheart.2008.01.002. Eur J Heart Fail. 2008. PMID: 18279775 Free article. Review.
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.
Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr, Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B, Zimmer C, Orlandi C, Gheorghiade M; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Wang NC, et al. Among authors: zannad f. JAMA. 2008 Jun 11;299(22):2656-66. doi: 10.1001/jama.299.22.2656. JAMA. 2008. PMID: 18544725
Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program.
Blair JE, Zannad F, Konstam MA, Cook T, Traver B, Burnett JC Jr, Grinfeld L, Krasa H, Maggioni AP, Orlandi C, Swedberg K, Udelson JE, Zimmer C, Gheorghiade M; EVEREST Investigators. Blair JE, et al. Among authors: zannad f. J Am Coll Cardiol. 2008 Nov 11;52(20):1640-8. doi: 10.1016/j.jacc.2008.07.056. J Am Coll Cardiol. 2008. PMID: 18992654 Free article. Clinical Trial.
Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial.
Blair JE, Khan S, Konstam MA, Swedberg K, Zannad F, Burnett JC Jr, Grinfeld L, Maggioni AP, Udelson JE, Zimmer CA, Ouyang J, Chen CF, Gheorghiade M; EVEREST Investigators. Blair JE, et al. Among authors: zannad f. Eur Heart J. 2009 Jul;30(13):1666-73. doi: 10.1093/eurheartj/ehp144. Epub 2009 May 2. Eur Heart J. 2009. PMID: 19411662 Clinical Trial.
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group.
Gheorghiade M, Adams KF, Cleland JG, Cotter G, Felker GM, Filippatos GS, Fonarow GC, Greenberg BH, Hernandez AF, Khan S, Komajda M, Konstam MA, Liu PP, Maggioni AP, Massie BM, McMurray JJ, Mehra M, Metra M, O'Connell J, O'Connor CM, Pang PS, Piña IL, Sabbah HN, Teerlink JR, Udelson JE, Yancy CW, Zannad F, Stockbridge N; Acute Heart Failure Syndromes International Working Group. Gheorghiade M, et al. Among authors: zannad f. Am Heart J. 2009 Jun;157(6):957-70. doi: 10.1016/j.ahj.2009.04.010. Am Heart J. 2009. PMID: 19464405 No abstract available.
1,150 results